A study has shown that circulating levels of A-FABP, also known as FABP4, are significantly higher in obese patients with breast cancer than in those without breast cancer, and circulating A-FABP enhances tumor stemness and aggressiveness by activating the IL-6/STAT3/ALDH1 pathway (133). Here, FABP4 is linked to breast cancer.